The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study

Prostate Cancer and Prostatic Diseases

Volumn 12, Issue 4, 2009, Pages 369-374

  Becher, E ^a   Roehrborn, C G ^b   Siami, P ^c   Gagnier, R P ^d   Wilson, T H ^d   Montorsi, F ^e  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Welborn Clinic   (United States)

^d GLAXOSMITHKLINE   (United States)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DISEASE PREDISPOSITION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; MONOTHERAPY; ORGAN SIZE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AZASTEROIDS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATISM; SULFONAMIDES; URINARY BLADDER, OVERACTIVE; URINATION;

EID: 70649104748     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2009.37     Document Type: Article

References (26)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 37-49.
2. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006; 50: 1306-1314; discussion 1314-1315.
3. Roehrborn CG. Combination medical therapy for lower urinary tract symptoms and benign prostatic hyperplasia. Rev Urol 2005; 7 (Suppl 8): S43-S51.
4. Rosenberg MT, Staskin DR, Kaplan SA, MacDiarmid SA, Newman DK, Ohl DA. A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract 2007; 61: 1535-1546.
5. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987-1006.
6. Garg G, Singh D, Saraf S. Management of benign prostate hyperplasia: An overview of alpha-adrenergic antagonist. Biol Pharm Bull 2006; 29: 1554-1558.
7. Nitti VW. Is there a role for alpha-blockers for the treatment of voiding dysfunction unrelated to benign prostatic hyperplasia? Rev Urol 2005; 7 (Suppl 4): S49-S55.
8. Rossi C, Kortmann BB, Sonke GS, Floratos DL, Kiemeney LA, Wijkstra H et al. Alpha-blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. J Urol 2001; 165: 38-41.
9. Malloy BJ, Price DT, Price RR, Bienstock AM, Dole MK, Funk BL et al. Alpha1-adrenergic receptor subtypes in human detrusor. J Urol 1998; 160 (Pt 1): 937-943.
10. Emberton M, Zinner N, Michel MC, Gittelman M, Chung MK, Madersbacher S. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: Therapeutic options for the man at risk. BJU Int 2007; 100: 249-253.
11. Issa MM, Kraft KH. 5alpha-reductase inhibition for men with enlarged prostate. J Am Acad Nurse Pract 2007; 19: 398-407.
12. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-441.
13. Kirby R, Lepor H In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds). Campbell-Walsh Urology, 9th edn. 2007, Saunders Elsevier: Philadelphia.
14. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Morrill B et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 616-621.
15. McConnell JD, Roehrborn CG, Bautista OM, Andriole Jr GL, Dixon CM, Kusek JW et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398.
16. Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan A et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: The CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 2007; 28: 770-779.
17. Roehrborn CG, Siami P, Barkin J, Damiao R, Becher E, Minana B et al. The influence of baseline parameters on changes in IPSS with dutasteride, tamsulosin and combination therapy among men with symptomatic BPH and an enlarged prostate (≥30 cc): Two-year data from the Combination of Avodart and Tamsulosin (CombAT) study. Eur Urol 2009; 55: 461-471.
18. Hakkinen JT, Hakama M, Huhtala H, Shiri R, Auvinen A, Tammela TL et al. Impact of LUTS using bother index in DAN-PSS-1 questionnaire. Eur Urol 2007; 51: 473-477; discussion 477-478.
19. Chatelain C, Denis L, Foo KT, Khoury S, McConnell J, Abrams P et al. Recommendations of the International Scientific Committee: Evaluation and treatment of lower urinary tract symptoms (LUTS) in older men. In: Chatelain C, Denis L, Foo KT, Khoury S, McConnell J (eds). Proceedings of the Fifth International Consultation on Benign Prostatic Hyperplasia. Health Publications Ltd: United Kingdom, 2001, pp 519-534.
20. Barry MJ, Williford WO, Fowler Jr FJ, Jones KM, Lepor H. Filling and voiding symptoms in the American Urological Association symptom index: the value of their distinction in a Veterans Affairs randomized trial of medical therapy in men with a clinical diagnosis of benign prostatic hyperplasia. J Urol 2000; 164: 1559-1564.
21. Roehrborn CG, McConnell JD, Saltzman B, Bergner D, Gray T, Narayan P et al. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol 2002; 42: 1-6.
22. Mirone V, Imbimbo C, Longo N, Fusco F. The detrusor muscle: An innocent victim of bladder outlet obstruction. Eur Urol 2007; 51: 57-66.
23. Kaplan SA, Roehrborn CG, McConnell JD, Meehan AG, Surynawanshi S, Lee JY et al. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J Urol 2008; 180: 1030-1032; discussion 1032-1033.
24. de Groat WC, Yoshiyama M, Ramage AG, Yamamoto T, Somogyi GT. Modulation of voiding and storage reflexes by activation of alpha1-adrenoceptors. Eur Urol 1999; 36 (Suppl 1): 68-73.
25. Kirby R, Andersson KE, Lepor H, Steers WD. Alpha(1)-Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. Prostate Cancer Prostatic Dis 2000; 3 76-83.
26. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: Correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001; 166: 550-552; discussion 553.